Blog Band - Page 278 of 299

22

Mar 2021

PharmaShots Interview: SiO2’s Lawrence Ganti Shares Insight on the Efforts to Scale Up the Manufacturing of Vials for COVID-19 Vaccines

In an interview with PharmaShots, Lawrence Ganti, President & Chief Business Officer at SiO2 Materials Science shared his views on the efforts to scale up the manufacturing of vials to combat COVID-19.…

19

Mar 2021

VIEWPOINTS

PharmaShots Interview: Biogen’s Wildon R. Farwell Shares Insight on Phase 4 RESPOND Study of Spinraza

In an interview with PharmaShots, Wildon R. Farwell, M.D., MPH, Global Medical Head of Neuromuscular Diseases at Biogen shared his views on the P-IV RESPOND study that assesses the benefits of Spinraza…

18

Mar 2021

INSIGHTS+

Insights+: The US FDA New Drug Approvals in February 2021

The US FDA has approved 7 NDAs and 1 BLA in Feb 2021, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation…

15

Mar 2021

VIEWPOINTS

PharmaShots Interview: Abbott’s Allen Burton Shares Insight on NeuroSphere myPath App

In an interview with PharmaShots, Allen Burton, M.D., Medical Director at Abbott Neuromodulation shared his views on the NeuroSphere myPath App which is designed to track and report pain relief in chronic pain…

12

Mar 2021

VIEWPOINTS

PharmaShots Interview: ViiV Healthcare’s Max Lataillade Shares Insight on Rukobia

In an interview with PharmaShots, Max Lataillade, Vice President, Head of Global Research Strategy, ViiV Healthcare shared his views on the development of Rukobia and the story of its development. He also…

11

Mar 2021

INSIGHTS+

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012 The Breakthrough Designation is granted to…

08

Mar 2021

VIEWPOINTS

PharmaShots Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen, the First Treatment for Leber Congenital Amaurosis 10 (LCA10)

In an interview with PharmaShots, Daniel A. de Boer of ProQR shared his views on P-II/III pivotal trial of Sepofarsen to treat the root cause of a rare eye disease, Leber congenital amaurosis 10 (LCA10)…

04

Mar 2021

INSIGHTS+

Insights+ Key Biosimilars Events of February 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded…

03

Mar 2021

VIEWPOINTS

PharmaShots Interview: PGDx’s Megan Bailey Shares Insight on the Partnership with QIAGEN and Almac

In an interview with PharmaShots, Megan Bailey, CEO of PGDx shared her views on PGDx's collaboration with QIAGEN and Almac to advance cancer diagnostics and make precision medicine more accessible to healthcare systems, laboratories,…

01

Mar 2021

VIEWPOINTS

PharmaShots Interview: Adagio Therapeutics’ Tillman Gerngross Shares Insight on the Development of Antibodies to Prevent COVID-19

In an interview with PharmaShots, Tillman Gerngross, Ph.D., Co-Founder, and CEO of Adagio Therapeutics shed light on the pre-clinical data of ADG2 and how it works on SARS-CoV-2. Shots: ADG2 showed broad and potent…

PharmaShots Interview: SiO2’s Lawrence Ganti Shares Insight on the Efforts to Scale Up the Manufacturing of Vials for COVID-19 Vaccines

PharmaShots Interview: Biogen’s Wildon R. Farwell Shares Insight on Phase 4 RESPOND Study of Spinraza

Insights+: The US FDA New Drug Approvals in February 2021

PharmaShots Interview: Abbott’s Allen Burton Shares Insight on NeuroSphere myPath App

PharmaShots Interview: ViiV Healthcare’s Max Lataillade Shares Insight on Rukobia

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

PharmaShots Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen, the First Treatment for Leber Congenital Amaurosis 10 (LCA10)

Insights+ Key Biosimilars Events of February 2021

PharmaShots Interview: PGDx’s Megan Bailey Shares Insight on the Partnership with QIAGEN and Almac

PharmaShots Interview: Adagio Therapeutics’ Tillman Gerngross Shares Insight on the Development of Antibodies to Prevent COVID-19

Contact US

OUR INFORMATION

FOLLOW US